SCHEMBL1594432

SCHEMBL1594432

ClCCCC1(c2ccccc2)OCCO1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HTR1A P08908 3/20 0.35
ADRA1D P25100 2/20 0.32
CHRM2 P08172 1/20 0.32
CHRM4 P08173 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C19 P33261 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
ICMT O60725 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11250471 0.95 L3MBTL1 (0.42) L3MBTL1TSHRMAPK1SMN1; SMN2HTR1A
SCHEMBL11240674 0.89 L3MBTL1 (0.45) L3MBTL1TSHRMAPK1SMN1; SMN2HTR1A
SCHEMBL11243389 0.88 TSHR (0.37) L3MBTL1TSHRMAPK1SMN1; SMN2HTR1A
SCHEMBL10339449 0.86 L3MBTL1 (0.46) L3MBTL1TSHRMAPK1SMN1; SMN2CHRM2
SCHEMBL1593553 0.86 LTA4H (0.39) TSHRHTR1A
SCHEMBL1593327 0.84 ALDH1A1 (0.33) TSHRMAPK1ALDH1A1MAOAMAOB
SCHEMBL10976001 0.83 GRIN1 (0.37) L3MBTL1TSHRMAPK1SMN1; SMN2HTR1A
SCHEMBL4053345 0.82 EGFR (0.32) SMN1; SMN2MEN1KMT2AMAOAMAOB
SCHEMBL4613107 0.82 L3MBTL1 (0.33) L3MBTL1KMT2AMAOAMAOB
SCHEMBL1594054 0.82 PKM (0.34) KDM4EALDH1A1CYP1A2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1924578-B1 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS LILLY CO ELI (US) 2013-11-06 EP disclosed
US-20130231360-A1 Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases THE BRIGHAM AND WOMEN S HOSPITAL, INC. (US) 2013-09-05 US disclosed
US-20130231360-A1 Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases THE BRIGHAM AND WOMEN S HOSPITAL, INC. (US) 2013-09-05 US disclosed
US-8217001-B2 Modification of feeding behavior IMPERIAL INNOVATIONS LIMITED 2012-07-10 US disclosed
WO-2011133795-A2 BETA-CARBOLINES AS INHIBITORS OF HASPIN AND DYRK KINASES THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2011-10-27 WO disclosed
US-7981882-B2 e.g. 7-Chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine; antidepressant, anxiolytic agent; obesity, obsessive/compulsive disorder ELI LILLY AND COMPANY (US) 2011-07-19 US disclosed
US-7919329-B2 Using proopiomelanocortin neuronal regulatory sequences to identify agents that affects caloric intake, energy expenditure, appetite or food intake; treating eating disorders and/or cachexia OREGON HEALTH & SCIENCE UNIVERSITY (US) 2011-04-05 US disclosed
US-20090209461-A1 MODIFICATION OF FEEDING BEHAVIOR IMPERIAL COLLEGE INNOVATIONS LTD. (GB) 2009-08-20 US disclosed
EP-2050460-A1 PYY and agonists thereof for modification of feeding behaviour Imperial Innovations Limited (GB) 2009-04-22 EP disclosed
US-7459432-B2 Modification of feeding behavior IMPERIAL COLLEGE INNOVATIONS LTD. (GB) 2008-12-02 US disclosed
WO-1997009311-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1997-03-13 WO disclosed
US-5610144-A CHOLECYSTOKININ OR GASTRIN ANTAGONISTS; NERVOUS SYSTEM AND GASTROINTESTINAL DISORDERS RHONE-POULENC RORER S.A. (FR) 1997-03-11 US disclosed
US-5089529-A Antiarrhythmia agents NIPPON SHINYAKU CO., LTD. (JP) 1992-02-18 US disclosed
US-4603134-A ANTIHISTAMINES FERRER INTERNATIONAL, S.A. (ES) 1986-07-29 US disclosed
US-4294986-A Novel para-phenylalkoxy phenylurea and thiourea compounds and herbicidal use thereof AMERICAN CYANAMID CO. (US) 1981-10-13 US disclosed
US-4289903-A PREEMERGENCE AND POSTEMERGENCE AMERICAN CYANAMID COMPANY (US) 1981-09-15 US disclosed
US-4258045-A 2,4-DIAMINO-5-((ARYLALKOXY)BENZYL)-PYRIMIDINES AS ANTIBACTERIAL, ANTIPROTOZOAL AND ANTITUMOR AGENTS MERCK & CO., INC. (US) 1981-03-24 US disclosed
US-4241070-A NONHABIT-FORMING SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1980-12-23 US disclosed
US-4101662-A DISUBSTITUTED PIPERIDINES A. H. ROBINS COMPANY, INCORPORATED (US) 1978-07-18 US disclosed
US-3997670-A HYPOLIPIDEMIC SANDOZ, INC. (US) 1976-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209461-A1 MODIFICATION OF FEEDING BEHAVIOR NPY4R, NPY5R, NPY2R L3MBTL1 1954/4885TSHR 120/4885MAPK1 3627/4885
US-20130231360-A1 Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases HASPIN, HIPK1, HIPK2 L3MBTL1 2915/4885TSHR 3225/4885MAPK1 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.